Skip to main content
SpringerLink
Log in

The Role of Somatostatin Analogues in Treatment of Acromegaly

  • Chapter
  • First Online:
Growth Hormone Related Diseases and Therapy

Part of the book series: Contemporary Endocrinology ((COE))

  • 1020 Accesses

Abstract

Somatostatin receptor ligand (SSRL) therapy is the mainstay of medical management of patients with acromegaly, either as adjuvant or primary therapy. Octreotide long-acting release (LAR) and lanreotide autogel (ATG) account for almost all clinical use of these analogues in acromegaly. SSRL acts via stimulation of one or more somatostatin receptor subtypes (SSTR1–5). Inhibition of GH secretion occurs primarily through SSTR2; however, SSTR1 and -5 also play a role. Anti-proliferative effects encompass cell cycle arrest and apoptosis for which SSTR3 is the predominant receptor subtype implicated. Octreotide LAR and lanreotide ATG improve symptoms in almost all patients, control GH and IGF-I secretion in around 60 and 50%, respectively, and inhibit tumoural growth in at least 98% of patients. Significant tumour shrinkage is observed in 40–70%. A greater incidence and magnitude of tumour shrinkage is seen in primary therapy compared with adjuvant therapy. Tolerability is generally good, though gastrointestinal side effects are frequent, but rapid tachyphlaxis occurs. Inhibition of insulin secretion leads to problems with carbohydrate handling and chronic use leads to formation of gallstones in up to 30% of patients. Recent advances support the use of both octreotide LAR and lanreotide ATG 6 weekly for some patients, and lanreotide ATG can be self-injected to improve convenience for the patient. Recent data suggest prolonged remission can occur following SSRL withdrawal in patients who achieve long-term control on treatment. Whether use of SSRL pre-operatively to induce tumour shrinkage improves the outcome of surgery remains controversial; however, there are undoubtedly benefits to reducing anaesthetic risk. Future improvements in SSRL take advantage of the synergy between SSTR subtypes, or the SSTR and dopaminergic systems. Two molecules are currently in clinical trials, pasireotide (SOM230) which has high affinity for SSTR1, 2, 3, and 5; and BIM23A760 which is a “dopastatin” and binds DR2 and SSTR2 and 5. In addition, the prospect of prolonged acting formulations of octreotide to improve patient convenience is also in development.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Krulich L, Dhariwal AP, McCann SM. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. Endocrinology. 1968;83(4):783–90.

    Article  PubMed  CAS  Google Scholar 

  2. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science. 1973;179(68):77–9.

    Article  PubMed  CAS  Google Scholar 

  3. Schonbrunn A. Somatostatin receptors present knowledge and future directions. Ann Oncol. 1999;10 Suppl 2:S17–21.

    Article  PubMed  Google Scholar 

  4. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003;24(1):28–47.

    Article  PubMed  CAS  Google Scholar 

  5. Lania A, Mantovani G, Spada A. Genetic abnormalities of somatostatin receptors in pituitary tumors. Mol Cell Endocrinol. 2008;286(1–2):180–6.

    Article  PubMed  CAS  Google Scholar 

  6. Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab. 2001;86(7):2976–81.

    Article  PubMed  CAS  Google Scholar 

  7. Hu C, Yi C, Hao Z, Cao S, Li H, Shao X, et al. The effect of somatostatin and SSTR3 on proliferation and apoptosis of gastric cancer cells. Cancer Biol Ther. 2004;3(8):726–30.

    Article  PubMed  CAS  Google Scholar 

  8. Saveanu A, Jaquet P, Brue T, Barlier A. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas. Mol Cell Endocrinol. 2008;286(1–2):206–13.

    Article  PubMed  CAS  Google Scholar 

  9. Zatelli MC, Piccin D, Tagliati F, Ambrosio MR, Margutti A, Padovani R, et al. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion. J Clin Endocrinol Metab. 2003;88(6):2797–802.

    Article  PubMed  CAS  Google Scholar 

  10. Zatelli MC, Piccin D, Tagliati F, Bottoni A, Ambrosio MR, Margutti A, et al. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro. J Mol Endocrinol. 2005;35(2):333–41.

    Article  PubMed  CAS  Google Scholar 

  11. Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab. 2004;89(4):1577–85.

    Article  PubMed  CAS  Google Scholar 

  12. Matrone C, Pivonello R, Colao A, Cappabianca P, Cavallo LM. Del Basso De Caro ML, et al. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Neuroendocrinology. 2004;79(3):142–8.

    Article  PubMed  CAS  Google Scholar 

  13. Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, et al. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab. 2000;85(2):781–92.

    Article  PubMed  CAS  Google Scholar 

  14. Tulipano G, Soldi D, Bagnasco M, Culler MD, Taylor JE, Cocchi D, et al. Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. Endocrinology. 2002;143(4):1218–24.

    Article  PubMed  CAS  Google Scholar 

  15. Murray RD, Kim K, Ren SG, Chelly M, Umehara Y, Melmed S. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest. 2004;114(3):349–56.

    PubMed  CAS  Google Scholar 

  16. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, et al. SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 1982;31(11):1133–40.

    Article  PubMed  CAS  Google Scholar 

  17. del Pozo E, Neufeld M, Schluter K, Tortosa F, Clarenbach P, Bieder E, et al. Endocrine profile of a long-acting somatostatin derivative SMS 201–995. Study in normal volunteers following subcutaneous administration. Acta Endocrinol (Copenh). 1986;111(4):433–9.

    Google Scholar 

  18. Barkan AL, Kelch RP, Hopwood NJ, Beitins IZ. Treatment of acromegaly with the long-acting somatostatin analog SMS 201–995. J Clin Endocrinol Metab. 1988;66(1):16–23.

    Article  PubMed  CAS  Google Scholar 

  19. Pieters GF, Smals AE, Smals AG, von Gennep JA, Kloppenborg PW. The effect of minisomatostatin on anomalous growth hormone responses in acromegaly. Acta Endocrinol (Copenh). 1987;114(4):537–42.

    CAS  Google Scholar 

  20. Battershill PE, Clissold SP. Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs. 1989;38(5):658–702.

    Article  PubMed  CAS  Google Scholar 

  21. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146(5):707–16.

    Article  PubMed  CAS  Google Scholar 

  22. Anthony LB. Long-acting formulations of somatostatin analogues. Ital J Gastroenterol Hepatol. 1999;31 Suppl 2:S216–8.

    PubMed  Google Scholar 

  23. Lancranjan I, Bruns C, Grass P, Jaquet P, Jervell J, Kendall-Taylor P, et al. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism. 1996;45(8 Suppl 1):67–71.

    Article  PubMed  CAS  Google Scholar 

  24. Chen T, Miller TF, Prasad P, Lee J, Krauss J, Miscik K, et al. Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. J Clin Pharmacol. 2000;40(5):475–81.

    Article  PubMed  Google Scholar 

  25. Jenkins PJ, Akker S, Chew SL, Besser GM, Monson JP, Grossman AB. Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clin Endocrinol (Oxf). 2000;53(6):719–24.

    Article  CAS  Google Scholar 

  26. Colao A, Auriemma RS, Rebora A, Galdiero M, Resmini E, Minuto F, et al. Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol (Oxf). 2009;71(2):237–45.

    Article  CAS  Google Scholar 

  27. Lombardi G, Minuto F, Tamburrano G, Ambrosio MR, Arnaldi G, Arosio M, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. J Endocrinol Invest. 2009;32(3):202–9.

    PubMed  CAS  Google Scholar 

  28. Bronstein M, Musolino N, Jallad R, Cendros JM, Ramis J, Obach R, et al. Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol (Oxf). 2005;63(5):514–9.

    Article  CAS  Google Scholar 

  29. Cendros JM, Peraire C, Troconiz IF, Obach R. Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel. Metabolism. 2005;54(10):1276–81.

    Article  PubMed  CAS  Google Scholar 

  30. Carlsen SM, Lund-Johansen M, Schreiner T, Aanderud S, Johannesen O, Svartberg J, et al. Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial. J Clin Endocrinol Metab. 2008;93(8):2984–90.

    Article  PubMed  CAS  Google Scholar 

  31. Vance ML, Harris AG. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group Arch Intern Med. 1991;151(8):1573–8.

    CAS  Google Scholar 

  32. Ezzat S, Snyder PJ, Young WF, Boyajy LD, Newman C, Klibanski A, et al. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med. 1992;117(9):711–8.

    PubMed  CAS  Google Scholar 

  33. Baldelli R, Colao A, Razzore P, Jaffrain-Rea ML, Marzullo P, Ciccarelli E, et al. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab. 2000;85(11):4099–103.

    Article  PubMed  CAS  Google Scholar 

  34. Verhelst JA, Pedroncelli AM, Abs R, Montini M, Vandeweghe MV, Albani G, et al. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. Eur J Endocrinol. 2000;143(5):577–84.

    Article  PubMed  CAS  Google Scholar 

  35. Freda PU, Katznelson L, van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005;90(8):4465–73.

    Article  PubMed  CAS  Google Scholar 

  36. Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab. 2003;88(7):3090–8.

    Article  PubMed  CAS  Google Scholar 

  37. Lancranjan I, Atkinson AB. Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group. Pituitary. 1999;1(2):105–14.

    Article  PubMed  CAS  Google Scholar 

  38. Ayuk J, Stewart SE, Stewart PM, Sheppard MC. Efficacy of Sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin Endocrinol (Oxf). 2004;60(3):375–81.

    Article  CAS  Google Scholar 

  39. Chanson P, Boerlin V, Ajzenberg C, Bachelot Y, Benito P, Bringer J, et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol (Oxf). 2000;53(5):577–86.

    Article  CAS  Google Scholar 

  40. Turner HE, Vadivale A, Keenan J, Wass JA. A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clin Endocrinol (Oxf). 1999;51(3):275–80.

    Article  CAS  Google Scholar 

  41. Cozzi R, Dallabonzana D, Attanasio R, Barausse M, Oppizzi G. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. Eur J Endocrinol. 1999;141(3):267–71.

    Article  PubMed  CAS  Google Scholar 

  42. Kendall-Taylor P, Miller M, Gebbie J, Turner S. al-Maskari M. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly Pituitary. 2000;3(2):61–5.

    CAS  Google Scholar 

  43. Ronchi CL, Orsi E, Giavoli C, Cappiello V, Epaminonda P, Beck-Peccoz P, et al. Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues. J Endocrinol Invest. 2003;26(6):533–8.

    PubMed  CAS  Google Scholar 

  44. Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab. 2008;93(8):2957–68.

    Article  PubMed  CAS  Google Scholar 

  45. Caron P, Beckers A, Cullen DR, Goth MI, Gutt B, Laurberg P, et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab. 2002;87(1):99–104.

    Article  PubMed  CAS  Google Scholar 

  46. Caron P, Bex M, Cullen DR, Feldt-Rasmussen U. Pico Alfonso AM, Pynka S, et al. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol (Oxf). 2004;60(6):734–40.

    Article  CAS  Google Scholar 

  47. Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf). 2006;64(2):209–14.

    Article  CAS  Google Scholar 

  48. Lucas T, Astorga R. Efficacy of lanreotide Autogel administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol (Oxf). 2006;65(3):320–6.

    Article  CAS  Google Scholar 

  49. Melmed S, Cook D, Schopohl J, Goth MI, Lam KS, Marek J. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary. 2010;13(1):18–28.

    Article  PubMed  CAS  Google Scholar 

  50. van Thiel SW, Romijn JA, Biermasz NR, Ballieux BE, Frolich M, Smit JW, et al. Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. Eur J Endocrinol. 2004;150(4):489–95.

    Article  PubMed  Google Scholar 

  51. Alexopoulou O, Abrams P, Verhelst J, Poppe K, Velkeniers B, Abs R, et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol. 2004;151(3):317–24.

    Article  PubMed  CAS  Google Scholar 

  52. Ashwell SG, Bevan JS, Edwards OM, Harris MM, Holmes C, Middleton MA, et al. The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. Eur J Endocrinol. 2004;150(4):473–80.

    Article  PubMed  CAS  Google Scholar 

  53. Ronchi CL, Boschetti M. Degli Uberti EC, Mariotti S, Grottoli S, Loli P, et al. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol (Oxf). 2007;67(4):512–9.

    CAS  Google Scholar 

  54. Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M. A 12-month randomized crossover study on the effects of lanreotide autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly. Clin Endocrinol (Oxf). 2007;68(3):473–80.

    Article  CAS  Google Scholar 

  55. Bevan JS, Newell-Price J, Wass JA, Atkin SL, Bouloux PM, Chapman J, et al. Home administration of lanreotide Autogel® by patients with acromegaly, or their partners, is safe and effective. Clin Endocrinol (Oxf). 2008;68(3):343–9.

    CAS  Google Scholar 

  56. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, et al. Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab. 1998;83(9):3034–40.

    Article  PubMed  CAS  Google Scholar 

  57. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab. 2001;86(6):2779–86.

    Article  PubMed  CAS  Google Scholar 

  58. Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE, et al. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab. 2002;87(10):4554–63.

    Article  PubMed  CAS  Google Scholar 

  59. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab. 2006;91(4):1397–403.

    Article  PubMed  CAS  Google Scholar 

  60. Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A, et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf). 2006;64(3):342–51.

    Article  CAS  Google Scholar 

  61. Mercado M, Borges F, Bouterfa H, Chang TC, Chervin A, Farrall AJ, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf). 2007;66(6):859–68.

    Article  CAS  Google Scholar 

  62. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, et al. Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol (Oxf). 2002;56(1):65–71.

    Article  CAS  Google Scholar 

  63. Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med. 2003;349(21):2023–33.

    Article  PubMed  CAS  Google Scholar 

  64. Ronchi CL, Rizzo E, Lania AG, Pivonello R, Grottoli S, Colao A, et al. Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal. Eur J Endocrinol. 2008;158(1):19–25.

    Article  PubMed  CAS  Google Scholar 

  65. Kokudo N, Kothary PC, Eckhauser FE, Raper SE. Inhibitory effects of somatostatin on rat hepatocyte proliferation are mediated by cyclic AMP. J Surg Res. 1991;51(2):113–8.

    Article  PubMed  CAS  Google Scholar 

  66. Ferjoux G, Bousquet C, Cordelier P, Benali N, Lopez F, Rochaix P, et al. Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol Paris. 2000;94(3–4):205–10.

    Article  PubMed  CAS  Google Scholar 

  67. Scambia G, Panici PB, Baiocchi G, Perrone L, Iacobelli S, Mancuso S. Antiproliferative effects of somatostatin and the somatostatin analog SMS 201–995 on three human breast cancer cell lines. J Cancer Res Clin Oncol. 1988;114(3):306–8.

    Article  PubMed  CAS  Google Scholar 

  68. Pagliacci MC, Tognellini R, Grignani F, Nicoletti I. Inhibition of human breast cancer cell (MCF-7) growth in vitro by the somatostatin analog SMS 201–995: effects on cell cycle parameters and apoptotic cell death. Endocrinology. 1991;129(5):2555–62.

    Article  PubMed  CAS  Google Scholar 

  69. Hofland LJ, van Koetsveld PM, Wouters N, Waaijers M, Reubi JC, Lamberts SW. Dissociation of antiproliferative and antihormonal effects of the somatostatin analog octreotide on 7315b pituitary tumor cells. Endocrinology. 1992;131(2):571–7.

    Article  PubMed  CAS  Google Scholar 

  70. Weckbecker G, Liu R, Tolcsvai L, Bruns C. Antiproliferative effects of the somatostatin analogue octreotide (SMS 201–995) on ZR-75-1 human breast cancer cells in vivo and in vitro. Cancer Res. 1992;52(18):4973–8.

    PubMed  CAS  Google Scholar 

  71. Santini V, Lamberts SW, Krenning EP, Backx B, Lowenberg B. Somatostatin and its cyclic octapeptide analog SMS 201–995 as inhibitors of proliferation of human acute lymphoblastic and acute myeloid leukemia. Leuk Res. 1995;19(10):707–12.

    Article  PubMed  CAS  Google Scholar 

  72. Florio T, Thellung S, Arena S, Corsaro A, Spaziante R, Gussoni G, et al. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. Eur J Endocrinol. 1999;141(4):396–408.

    Article  PubMed  CAS  Google Scholar 

  73. Bevan JS. Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab. 2005;90(3):1856–63.

    Article  PubMed  CAS  Google Scholar 

  74. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20(3):157–98.

    Article  PubMed  CAS  Google Scholar 

  75. Weckbecker G, Raulf F, Bodmer D, Bruns C. Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice. Yale J Biol Med. 1997;70(5–6):549–54.

    PubMed  CAS  Google Scholar 

  76. Garcia de la Torre N, Wass JA, Turner HE. Antiangiogenic effects of somatostatin analogues. Clin Endocrinol (Oxf) 2002;57(4):425–41.

    Google Scholar 

  77. Florio T, Morini M, Villa V, Arena S, Corsaro A, Thellung S, et al. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology. 2003;144(4):1574–84.

    Article  PubMed  CAS  Google Scholar 

  78. Kumar M, Liu ZR, Thapa L, Chang Q, Wang DY, Qin RY. Antiangiogenic effect of somatostatin receptor subtype 2 on pancreatic cancer cell line: Inhibition of vascular endothelial growth factor and matrix metalloproteinase-2 expression in vitro. World J Gastroenterol. 2004;10(3):393–9.

    PubMed  CAS  Google Scholar 

  79. Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol. 1996;10(12):1688–96.

    Article  PubMed  CAS  Google Scholar 

  80. He Y, Yuan XM, Lei P, Wu S, Xing W, Lan XL, et al. The antiproliferative effects of somatostatin receptor subtype 2 in breast cancer cells. Acta Pharmacol Sin. 2009;30(7):1053–9.

    Article  PubMed  CAS  Google Scholar 

  81. Teijeiro R, Rios R, Costoya JA, Castro R, Bello JL, Devesa J, et al. Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53. Cell Physiol Biochem. 2002;12(1):31–8.

    Article  PubMed  CAS  Google Scholar 

  82. Sharma K, Patel YC, Srikant CB. C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest. Mol Endocrinol. 1999;13(1):82–90.

    Article  PubMed  CAS  Google Scholar 

  83. Buscail L, Esteve JP, Saint-Laurent N, Bertrand V, Reisine T, O’Carroll AM, et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci U S A. 1995;92(5):1580–4.

    Article  PubMed  CAS  Google Scholar 

  84. Cordelier P, Esteve JP, Bousquet C, Delesque N, O’Carroll AM, Schally AV, et al. Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. Proc Natl Acad Sci U S A. 1997;94(17):9343–8.

    Article  PubMed  CAS  Google Scholar 

  85. Li M, Wang X, Li W, Li F, Yang H, Wang H, et al. Somatostatin receptor-1 induces cell cycle arrest and inhibits tumor growth in pancreatic cancer. Cancer Sci. 2008;99(11):2218–23.

    Article  PubMed  CAS  Google Scholar 

  86. Florio T, Thellung S, Corsaro A, Bocca L, Arena S, Pattarozzi A, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin Endocrinol (Oxf). 2003;59(1):115–28.

    Article  CAS  Google Scholar 

  87. Losa M, Ciccarelli E, Mortini P, Barzaghi R, Gaia D, Faccani G, et al. Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas. J Clin Endocrinol Metab. 2001;86(11):5194–200.

    Article  PubMed  CAS  Google Scholar 

  88. Thapar K, Kovacs KT, Stefaneanu L, Scheithauer BW, Horvath E, Lloyd RV, et al. Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial. Mayo Clin Proc. 1997;72(10):893–900.

    Article  PubMed  CAS  Google Scholar 

  89. Ezzat S, Horvath E, Harris AG, Kovacs K. Morphological effects of octreotide on growth hormone-producing pituitary adenomas. J Clin Endocrinol Metab. 1994;79(1):113–8.

    Article  PubMed  CAS  Google Scholar 

  90. Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab. 2005;90(7):4405–10.

    Article  PubMed  CAS  Google Scholar 

  91. Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, et al. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf). 2007;67(2):282–9.

    Article  CAS  Google Scholar 

  92. Plockinger U, Reichel M, Fett U, Saeger W, Quabbe HJ. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab. 1994;79(5):1416–23.

    Article  PubMed  CAS  Google Scholar 

  93. Abe T, Ludecke DK. Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol. 2001;145(2):137–45.

    Article  PubMed  CAS  Google Scholar 

  94. Lucas T, Astorga R, Catala M. Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage. Clin Endocrinol (Oxf). 2003;58(4):471–81.

    Article  CAS  Google Scholar 

  95. Attanasio R, Barausse M, Cozzi R. GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide. J Endocrinol Invest. 2001;24(4):209–16.

    PubMed  CAS  Google Scholar 

  96. Casarini AP, Pinto EM, Jallad RS, Giorgi RR, Giannella-Neto D, Bronstein MD. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest. 2006;29(9):826–30.

    PubMed  CAS  Google Scholar 

  97. Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A, et al. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab. 2007;92(5):1592–9.

    Article  PubMed  CAS  Google Scholar 

  98. Ip MS, Tan KC, Peh WC, Lam KS. Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clin Endocrinol (Oxf). 2001;55(4):477–83.

    Article  CAS  Google Scholar 

  99. Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2007;92(5):1743–7.

    Article  PubMed  CAS  Google Scholar 

  100. Fatti LM, Scacchi M, Lavezzi E. Pecori Giraldi F, De Martin M, Toja P, et al. Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients. Clin Endocrinol (Oxf). 2006;65(5):626–30.

    Article  CAS  Google Scholar 

  101. Hansen I, Tsalikian E, Beaufrere B, Gerich J, Haymond M, Rizza R. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol. 1986;250(3 Pt 1):E269–73.

    PubMed  CAS  Google Scholar 

  102. Moller N, Petrany G, Cassidy D, Sheldon WL, Johnston DG, Laker MF. Effects of the somatostatin analogue SMS 201–995 (sandostatin) on mouth-to-caecum transit time and absorption of fat and carbohydrates in normal man. Clin Sci (Lond). 1988;75(4):345–50.

    CAS  Google Scholar 

  103. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab. 2009;94(5):1500–8.

    Article  PubMed  CAS  Google Scholar 

  104. Paisley AN, Roberts ME, Trainer PJ. Withdrawal of somatostatin analogue therapy in patients with acromegaly is associated with an increased risk of acute biliary problems. Clin Endocrinol (Oxf). 2007;66(5):723–6.

    Article  CAS  Google Scholar 

  105. Rideout DJ, Graham MM. Buttock granulomas: a consequence of intramuscular injection of Sandostatin detected by In-111 octreoscan. Clin Nucl Med. 2001;26(7):650.

    Article  PubMed  CAS  Google Scholar 

  106. Jallad RS, Musolino NR, Salgado LR, Bronstein MD. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf). 2005;63(2):168–75.

    Article  CAS  Google Scholar 

  107. Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, Kelch RP, et al. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201–995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab. 1988;67(5):1040–8.

    Article  PubMed  CAS  Google Scholar 

  108. Spinas GA, Zapf J, Landolt AM, Stuckmann G, Froesch ER. Pre-operative treatment of 5 acromegalics with a somatostatin analogue: endocrine and clinical observations. Acta Endocrinol (Copenh). 1987;114(2):249–56.

    CAS  Google Scholar 

  109. Stevenaert A, Harris AG, Kovacs K, Beckers A. Presurgical octreotide treatment in acromegaly. Metabolism. 1992;41(9 Suppl 2):51–8.

    Article  PubMed  CAS  Google Scholar 

  110. Colao A, Ferone D, Cappabianca P. del Basso De Caro ML, Marzullo P, Monticelli A, et al. Effect of octreotide pretreatment on surgical outcome in acromegaly J Clin Endocrinol Metab. 1997;82(10):3308–14.

    CAS  Google Scholar 

  111. Stevenaert A, Beckers A. Presurgical octreotide: treatment in acromegaly. Metabolism. 1996;45(8 Suppl 1):72–4.

    Article  PubMed  CAS  Google Scholar 

  112. Lucas-Morante T, Garcia-Uria J, Estrada J, Saucedo G, Cabello A, Alcaniz J, et al. Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201–995 before transsphenoidal surgery. J Neurosurg. 1994;81(1):10–4.

    Article  PubMed  CAS  Google Scholar 

  113. Stevenaert A, Beckers A. Presurgical octreotide treatment in acromegaly. Acta Endocrinol (Copenh). 1993;129 Suppl 1:18–20.

    Google Scholar 

  114. Biermasz NR, van Dulken H, Roelfsema F. Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab. 1999;84(10):3551–5.

    Article  PubMed  CAS  Google Scholar 

  115. Lissett CA, Peacey SR, Laing I, Tetlow L, Davis JR, Shalet SM. The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone (GH) secreting adenoma. Clin Endocrinol (Oxf). 1998;49(5):653–7.

    Article  CAS  Google Scholar 

  116. Reubi JC, Landolt AM. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab. 1989;68(4):844–50.

    Article  PubMed  CAS  Google Scholar 

  117. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, et al. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab. 2001;86(1):140–5.

    Article  PubMed  CAS  Google Scholar 

  118. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest. 1997;99(4):789–98.

    Article  PubMed  CAS  Google Scholar 

  119. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors J Clin Invest. 1997;100(9):2386–92.

    CAS  Google Scholar 

  120. Tulipano G, Bonfanti C, Milani G, Billeci B, Bollati A, Cozzi R, et al. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro. Neuroendocrinology. 2001;73(5):344–51.

    Article  PubMed  CAS  Google Scholar 

  121. Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, et al. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol. 2005;153(1):135–41.

    Article  PubMed  CAS  Google Scholar 

  122. Grant M, Patel RC, Kumar U. The role of subtype-specific ligand binding and the C-tail domain in dimer formation of human somatostatin receptors. J Biol Chem. 2004;279(37):38636–43.

    Article  PubMed  CAS  Google Scholar 

  123. Pfeiffer M, Koch T, Schroder H, Klutzny M, Kirscht S, Kreienkamp HJ, et al. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J Biol Chem. 2001;276(17):14027–36.

    PubMed  CAS  Google Scholar 

  124. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem. 2000;275(11):7862–9.

    Article  PubMed  CAS  Google Scholar 

  125. Sharif N, Gendron L, Wowchuk J, Sarret P, Mazella J, Beaudet A, et al. Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2. Endocrinology. 2007;148(5):2095–105.

    Article  PubMed  CAS  Google Scholar 

  126. Weckbecker G, Briner U, Lewis I, Bruns C. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology. 2002;143(10):4123–30.

    Article  PubMed  CAS  Google Scholar 

  127. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science. 2000;288(5463):154–7.

    Article  PubMed  CAS  Google Scholar 

  128. Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, et al. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab. 2002;87(12):5545–52.

    Article  PubMed  CAS  Google Scholar 

  129. Melmed S, Ho K, Klibanski A, Reichlin S, Thorner M. Clinical review 75: Recent advances in pathogenesis, diagnosis, and management of acromegaly. J Clin Endocrinol Metab. 1995;80(12):3395–402.

    Article  PubMed  CAS  Google Scholar 

  130. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998;83(2):374–8.

    Article  PubMed  CAS  Google Scholar 

  131. Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, et al. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab. 1997;82(2):518–23.

    Article  PubMed  CAS  Google Scholar 

  132. Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf). 2004;61(2):209–15.

    Article  CAS  Google Scholar 

  133. Lamberts SW, Zweens M, Verschoor L, del Pozo E. A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201–995, bromocriptine, and the combination of both drugs. J Clin Endocrinol Metab. 1986;63(1):16–9.

    Article  PubMed  CAS  Google Scholar 

  134. Baragli A, Alturaihi H, Watt HL, Abdallah A, Kumar U. Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signal. 2007;19(11):2304–16.

    Article  PubMed  CAS  Google Scholar 

  135. Ren SG, Kim S, Taylor J, Dong J, Moreau JP, Culler MD, et al. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J Clin Endocrinol Metab. 2003;88(11):5414–21.

    Article  PubMed  CAS  Google Scholar 

  136. Murray RD, Kim K, Ren SG, Lewis I, Weckbecker G, Bruns C, et al. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab. 2004;89(6):3027–32.

    Article  PubMed  CAS  Google Scholar 

  137. Ma P, Wang Y, van der Hoek J, Nedelman J, Schran H, Tran LL, et al. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly. Clin Pharmacol Ther. 2005;78(1):69–80.

    Article  PubMed  CAS  Google Scholar 

  138. van der Hoek J, de Herder WW, Feelders RA, van der Lely AJ, Uitterlinden P, Boerlin V, et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab. 2004;89(2):638–45.

    Article  PubMed  CAS  Google Scholar 

  139. van der Hoek J, van der Lelij AJ, Feelders RA, de Herder WW, Uitterlinden P, Poon KW, et al. The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients. Clin Endocrinol (Oxf). 2005;63(2):176–84.

    Article  CAS  Google Scholar 

  140. Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab. 2010;95(6):2781–9.

    Article  PubMed  CAS  Google Scholar 

  141. Schmid HA, Brueggen J, Guitard P. Effects of a long-acting release formulation of pasireotide (SOM230) on hormone secretion in rats. In: 89th Annual Meeting of the American Endocrine Society; 2007; Toronto. Canada; 2007 June;2007:P3–337.

    Google Scholar 

  142. Petersenn S, Bollerslev J, Arafat AM, Glusman JE, Serri O, Hu M, et al. Pasireotide LAR shows efficacy in patients with acromegaly: interim results from a randomised, multi-centre, phartmacokinetic/pharmacodynamic, phase I study. In: 90th Annual Meeting of the American Endocrine Society, San Francisco; June 2008. p. OR41–5.

    Google Scholar 

  143. Gruszka A, Ren SG, Dong J, Culler MD, Melmed S. Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology. 2007;148(12):6107–14.

    Article  PubMed  CAS  Google Scholar 

  144. Saveanu A, Gunz G, Guillen S, Dufour H, Culler MD, Jaquet P. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology. 2006;83(3–4):258–63.

    Article  PubMed  CAS  Google Scholar 

  145. Open label study of octreotide implant in patients with acromegaly. http://clinicaltrials.gov/ct2/show/NCT00913055. Accessed 17 Oct 2010.

  146. Efficacy and safety study of octreotide implant in patients with acromegaly. http://clinicaltrials.gov/ct2/show/NCT00765323. Accessed 17 Oct 2010.

  147. Ambrillia product pipeline: acromegaly – octreotide (C2L) http://www.ambrilia.com/en/products/acromegaly-octreotide.php. Accessed 17 Oct 2010.

  148. Ambrilla biopharma announces positive phase III results for octreotide C2L. http://www.drugs.com/clinical_trials/ambrilla-biopharma-announces-positive-phase-iii-results-octreotide-c2l-4260.html. Accessed 17 Oct 2010.

  149. Efficacy and safety of C2L-OCT-01 PR in acromegalic patients http://clinicaltrials.gov/ct2/show/NCT00616551. Accessed 17 Oct 2010.

  150. Safety and biological activity of C2L-OCT-01 PR in acromegalic patients. http://clinicaltrials.gov/ct2/show/NCT00642421. Accessed 17 Oct 2010.

  151. QLT delays initiation of phase IIa atrigel/octreotide program. http://qltinc.com/newsCenter/2006/060518.htm. Accessed 17 Oct 2010.

  152. Fusco A, Gunz G, Jaquet P, Dufour H, Germanetti AL, Culler MD, et al. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. Eur J Endocrinol. 2008;158(5):595–603.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology, Leeds Teaching Hospitals NHS Trust, Leeds, UK

    Haliza Haniff & Robert D. Murray

Authors
  1. Haliza Haniff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert D. Murray
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert D. Murray .

Editor information

Editors and Affiliations

  1. Princess Alexandra Hospital &, The University of Queensland, Centres for Health Research, Ipswich Road Woolloongabba 199, Brisbane, 4102, Queensland, Australia

    Ken Ho

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Haniff, H., Murray, R.D. (2011). The Role of Somatostatin Analogues in Treatment of Acromegaly. In: Ho, K. (eds) Growth Hormone Related Diseases and Therapy. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-60761-317-6_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-317-6_14

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-316-9

  • Online ISBN: 978-1-60761-317-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation